Navigation Links
Diopsys Receives CE Mark for its VEP Vision Testing Systems
Date:11/2/2011

PINE BROOK, N.J., Nov. 2, 2011 /PRNewswire/ -- Diopsys, Inc. announced today that its Visual Evoked Potential (VEP) Vision Testing Systems have been awarded the CE mark. The company has begun a roll-out of its patented vision testing devices to EU customers.

Diopsys completed a rigorous inspection of its total quality system in order to qualify for CE status.  "Having the CE mark opens many opportunities for us to provide clinicians and patients across the EU access to our advanced VEP technology," says Joseph Fontanetta, CEO of Diopsys, "Our VEP devices are designed to be used in an office setting and our patented technology overcomes many limitations of traditional VEP devices. Testing times are much faster than older VEP devices and our reports are easier to interpret. We are proud to bring an operator-friendly, objective, functional vision test to patients in need."

Diopsys is the developer and marketer of the Diopsys® NOVA-VEP Vision Testing Systems utilized by ophthalmologists and optometrists to aid in the detection, diagnosis and treatment of vision disorders, including glaucoma, a disease affecting millions globally. The company has also developed and markets the Enfant® Pediatric VEP Vision Testing System, a device used to test for visual deficits, including amblyopia, in children as young as six months of age.

Visual Evoked Potentials (VEPs) are electrical signals that are a measure of the electrophysiological activity at the visual cortex. VEP results are a representation of the functional integrity of all levels of the visual pathway including the eye, retina, optic nerve, and visual cortex. This technology has been used for a variety of applications that involve neuro-visual disorders such as glaucoma, amblyopia, multiple sclerosis and diabetic retinopathy, among many others.(1,2,3,4 )

About Diopsys

Diopsys, Inc. (www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing Visual Evoked Potential (VEP) technology.

References

1. Prata TS, Lima VC, De Moraes CG, Trubnik V, Derr P, Liebmann JM, Ritch R, Tello C. Short Duration Transient Visual Evoked Potentials in Glaucomatous Eyes. J Glaucoma. 2011 May 10. [Epub ahead of print]

2. Simon J, Siegfried J, Mills M, Calhoun J, Gurland J. A New Visual Evoked Potential System for Vision Screening in Infants and Young Children. Journal of AAPOS. 8.6 (2004): 549-554.


3. Garcia-Martin E, Pueyo V, Ara JR, Almarcegui C, Martin J, Pablo L, Dolz I, Sancho E, Fernandez FJ. Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients. Mult Scler. 2011 Jul;17(7):830-7. Epub 2011 Feb 7.

4. Parisi V, Uccioli L. Visual electrophysiological responses in persons with type 1 diabetes. Diabetes Metab Res Rev. 2001 Jan-Feb;17(1):12-8.


'/>"/>
SOURCE Diopsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diopsys, Inc. Launches New Website for Doctors and Patients, www.Diopsys.com
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... remain until legal experts and senior industry leaders involved in supply chain, ... to discuss the flow of pharmaceutical products post Brexit at the only ... In the run up to the show, SMi Group have ... the event download centre . ... Some of those confirmed include: EMA, Aeterna Zentaris, ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, ... HIV/AIDS etc.), Forecast to 2022" report to their offering. ... US ... clinical lab testing, which has evolved as a major source ...
(Date:1/21/2017)... , January 20, 2017 According to ... (Descriptive, Prescriptive), Application (Marketing, R&D, Compliance, SCM), Component (Software, Service), Delivery ... Forecasts to 2021" published by MarketsandMarkets, the market is expected to ... 2016, at a CAGR of 13.3% during the forecast period. ... ...
Breaking Medicine Technology:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set of camera tools ... create dynamic looks in Final Cut Pro X," said Christina Austin - CEO of Pixel ... to two layers of text with video footage. ProRandom works by using a virtual ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: a moving and eloquent ... life. “Crossing the Bar” is the creation of published author, Charlotte Hotte, a North ... who credits the inspiration of the book to her sister, Denise, wishes to acknowledge ...
(Date:1/22/2017)... ... , ... Phytocéane invites clients to take an exotic journey deep into the ... MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off the coast ... coral to create this gentle, velvety body cream to envelop the skin in moisture ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... Salveo for ... it is bringing its product to the United States as part of its presence ... last 25 years, Alcovit aims to reduce the productions of nasty toxins as a ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Dermatology has recently joined their multi-specialty medical group. The dermatology practice provides ... services. , “We’re excited to add this excellent dermatology practice to our group’s ...
Breaking Medicine News(10 mins):